{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-029123","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.171142+00:00","generated_at":"2026-06-24T00:50:01.289659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevi Q2 net loss narrows to $8.1M; Haduvio achieves all endpoints in Phase 2b/3 prurigo nodularis trial","bullets":["Q2 2022 net loss of $8.1M ($9.8M in Q2 2021); cash and securities $78.9M.","Phase 2b/3 PRISM trial met primary endpoint (25% vs 14% WI-NRS 4-point reduction, p=0.0157) and all key secondary endpoints with statistical significance.","Completed $55M private placement in April 2022 to fund clinical development of Haduvio.","Topline data from Phase 2 CANAL chronic cough in IPF trial expected Q3 2022; FDA meeting scheduled for this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-029123","json":"https://secwatch.observer/filing/0001564590-22-029123.json","markdown":"https://secwatch.observer/filing/0001564590-22-029123.md","text":"https://secwatch.observer/filing/0001564590-22-029123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/0001564590-22-029123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/trvi-8k_20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:50:01.289659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}